Terlipressin is an investigational agent and its safety and effectiveness have not yet been established by the
The results shared in an oral presentation titled “Terlipressin Improves Renal Replacement Therapy–Free Survival in Hepatorenal Syndrome Type 1” included a post-hoc analysis to assess the incidence of RRT among patients from the CONFIRM (NCT 02770716), REVERSE (NCT 01143246) and OT-0401 (NCT 00089570) Phase 3 trials. Results from this pooled analysis showed: at Day 30, 26 percent in the terlipressin group (56/218) needed RRT compared with 42 percent of those on placebo (70/166); at Day 60, 27 percent of the terlipressin group (52/193) required RRT versus 45 percent on placebo (64/143); and at Day 90, 29 percent of surviving patients in the terlipressin group (52/182) needed RRT compared with 45 percent in the placebo group (60/133).2
The pooled analysis also showed that RRT-free 90-day survival was higher among patients treated with terlipressin versus placebo in all three trials. The pooled RRT-free survival rate for patients treated with terlipressin was 37 percent (130/352) versus 29 percent in the placebo group (73/256) across the three trials (p=0.03).2 The presentation can be accessed here on the company’s website.
“The findings presented from the post-hoc and pooled analyses support the positive results of the Phase 3 CONFIRM trial among HRS-1 patients, showing the potential for terlipressin to help patients reduce the need for renal replacement therapy and improve RRT-free survival,” said presenting author
Limitations of a pooled analysis such as this include a reliance on the quality or reporting of the original study results. In addition, the variability of patient populations, the quality of the data and the potential for underlying biases are not addressed.
A second data set was presented in a poster presentation titled, “Treatment of Hepatorenal Syndrome Type 1 with Terlipressin Reduces Need for Renal Replacement Therapy After Liver Transplantation,” including a post-hoc analysis of the CONFIRM study which evaluated the need for RRT among patients who had liver transplantation at 90 days. The study found that patients treated with terlipressin had a lower rate of RRT following liver transplantation compared to patients treated with placebo (19.6 percent (9/46) versus 44.8 percent (13/29); p=0.036). The poster also included a pooled analysis which assessed survival rates from the three terlipressin Phase 3 clinical trials for patients following liver transplantation. The analysis found that at Day 90, 50 percent of patients treated with terlipressin (46/92) were alive without receiving RRT compared with 32.2 percent in the placebo group (19/59; p=0.032).3 The poster can be accessed here on the company’s website.
“Mallinckrodt remains committed to furthering our understanding of HRS-1 and terlipressin to address HRS-1, where a patient’s condition can deteriorate rapidly and treatment options are limited,” said
Terlipressin is approved in many countries outside
HRS-1 has a median survival time of less than two weeks and greater than 80 percent mortality within three months if left untreated.7,8 At present, there are no approved drug therapies for HRS-1 in the
The studies were funded by Mallinckrodt.
Terlipressin is a potent vasopressin analogue selective for V1 receptors being investigated for the treatment of HRS-1 in the
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CAUTIONARY STATEMENTS RELATED TO FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements with regard to terlipressin, including its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; issues with product quality, manufacturing or supply, or patient safety issues; and other risks identified and described in more detail in the “Risk Factors” section of Mallinckrodt’s most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and Mallinckrodt does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2020 Mallinckrodt. US-2000031 10/20
1 National Organization for Rare Disorders. Hepatorenal Syndrome. Available at: https://rarediseases.org/rare-diseases/hepatorenal-syndrome/. Accessed
2 Data on file – ref-04410.
3 Data on file – ref-04409.
4 De Franchis R. Evolving Consensus in Portal Hypertension Report of the
5 Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews. 2003;1. doi: 10.1002/14651858.CD002147.
6 European Association for the Study of the Liver (EASL). Clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460.
7 Colle I and Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Review of Gastroenterology & Hepatology. (2018) 12:2, 173-188, DOI: 10.1080/17474124.2018.1417034.
8 Gines P, Sola E, Angeli P, et al. Hepatorenal syndrome. Nature Reviews. (2018) 4:23.
9 Boyer TD, Medicis JJ, Pappas SC, et al. A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design. Open Access Journal of Clinical Trials 2012:4. https://www.dovepress.com/a-randomized-placebo-controlled-double-blind-study-to-confirm-the-reve-peer-reviewed-article-OAJCT.
10 C Pant, B S Jani, M Desai, A Deshpande,
11 United States Census Bureau: Quick Facts. Available at: https://www.census.gov/quickfacts/fact/table/US/PST045218. Accessed October 16, 2020.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-announces-data-at-kidney-week-2020-reimagined-that-showed-a-potential-for-reduced-need-for-renal-replacement-rrt-therapy-for-patients-with-hepatorenal-syndrome-type-1-hrs-1-treated-with-terlipressin-301162369.html